Sub-Navigation

• Calendar
• Live Events
  • Q2 2008 Investor Conference Call
  • Rivaroxaban Data at EFORT 2008
  • Q1 2008 Investor Conference Call
  • FY/Q4 2007 Investor Conference Call
  • Test your player
• Investor Conferences
• Stockholders' Meeting
• Press Conferences
• Roadshows
• Other Presentations
• Archive

Bayer Links

• Bayer Global
• Sustainability
• Press

Additionals

• General Conditions of Use
• Privacy Statement
• Imprint
• Technical Details

Klickpfad

• Home
• Events
• Live Events
• Rivaroxaban Data at EFORT 2008

May 29 - June 1, 2008
Nice, France

Rivaroxaban data from the RECORD4 clinical trial have been presented at the annual meeting of the European Federation of National Associations of Orthopaedics and Traumatology (EFORT).

Friday, May 30, 2008 at 05:30 p.m. CEST (3:30 p.m. GMT): Investor Conference Call - Review of Rivaroxaban Data at EFORT Congress

with
Alexander G.G. Turpie, M.D., Chair of the steering committee and lead investigator RECORD4 study
Dr. Kemal Malik, Head of Global Development at Bayer Schering
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations

On-demand audio recording of the presentation and discussion

Audio as MP3 and Podcast

• Background Information

• List of Abstracts

  

Background Information
About Rivaroxaban	PDF / 81 KB collectAbout_Rivaroxaban_2008-05.pdf About Rivaroxaban
About RECORD Studies	PDF / 62 KB collectAbout_RECORD_Studies_2008-05.pdf About RECORD Studies
About Rivaroxaban Clinical Studies	PDF / 70 KB collectAbout_Rivaroxaban_Clinical_Studies_2008-05.pdf About Rivaroxaban Clinical Studies
History Of Anticoagulants	PDF / 358 KB collectHistory_of_anticoagulants_2008-05.pdf History of Anticoagulants
Understanding Venous Blood Clots	PDF / 52 KB collectUnderstanding_venous_blood_clots_2008-05.pdf Understanding Venous Blood Clots
Glossary	PDF / 39 KB collectGlossary_2008-05.pdf Glossary

List of EFORT 2008 Abstracts on Rivaroxaban:

• Prevention of venous thromboembolism with rivaroxaban after total hip replacement: economic impact of extended thromboprophylaxis
• Rivaroxaban for prevention of venous thromboembolism after total hip replacement: impact on healthcare costs based on the RECORD1 study
• Rivaroxaban for thromboprophylaxis after total knee replacement: the RECORD3 trial
• Comparison of rivaroxaban – an oral, direct Factor Xa inhibitor – and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD4: a phase III study)
• Comparison of oral rivaroxaban and subcutaneous enoxaparin for extended thromboprophylaxis following total hip replacement: RECORD1
• An evaluation of the efficacy and safety of extended thromboprophylaxis with oral rivaroxaban compared with short-term subcutaneous enoxaparin following total hip replacement (RECORD2: a phase III study)